Bayer invests for expansion in the Animal Health sector

AFP PHOTO / John Macdougall

Bayer aims to further grow its Animal Health Business. Until 2021, the company plans to invest around 92 million euros into the further development of the production site in Kiel, where some of the most important products for the global market are being manufactured.
Kiel is by far the most important production site for our animal health business, said Dr. Dirk Ehle, Head of the Bayer unit Animal Health. Here, we produce around 60 percent of our products, which are sold all over the globe.
2016, total Animal Health sales came in at around 1.5 billion euros. Other production sites are located in the USA, South Korea, China, Vietnam, Brazil, Mexico and New Zealand.

Bayer: Science for a better life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015.

For more information, go to